"Patient advocates starting getting very nervous" about the obstacles in getting psychiatric medications, and their lobbying convinced the state program to delete the antipsychotics from the preauthorization requirement. It did, however, leave in place the Food and Drug Administration’s (FDA) dose guidelines, thus prohibiting "off-label dosing," he noted.